tiprankstipranks
Advertisement
Advertisement

TEVA Stock Latest News

Teva put volume heavy and directionally bearish
The FlyTeva put volume heavy and directionally bearish
5h ago
TEVA
Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?
PremiumMarket News
Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?
2d ago
CORT
TEVA
Enphase, AST SpaceMobile, AppLovin, ConocoPhillips, Teva Shock
PremiumWeekend Updates
Enphase, AST SpaceMobile, AppLovin, ConocoPhillips, Teva Shock
6d ago
APP
COP
Teva price target raised to $41 from $40 at Piper Sandler
PremiumThe Fly
Teva price target raised to $41 from $40 at Piper Sandler
23d ago
TEVA
Teva, Blackstone announce $400M strategic funding agreement for duvakitug
PremiumThe Fly
Teva, Blackstone announce $400M strategic funding agreement for duvakitug
24d ago
BX
SNY
Unusually active option classes on open February 24th
PremiumThe FlyUnusually active option classes on open February 24th
1M ago
F
HD
FDA accepts Teva NDA for olanzapine extended-release injectable suspension
Premium
The Fly
FDA accepts Teva NDA for olanzapine extended-release injectable suspension
1M ago
TEVA
Teva management to meet with Piper Sandler
Premium
The Fly
Teva management to meet with Piper Sandler
1M ago
TEVA
Corcept Therapeutics price target lowered to $67 from $105 at H.C. Wainwright
PremiumThe Fly
Corcept Therapeutics price target lowered to $67 from $105 at H.C. Wainwright
1M ago
CORT
TEVA
Corcept ‘disappointed’ in court ruling over Teva patent dispute
PremiumThe Fly
Corcept ‘disappointed’ in court ruling over Teva patent dispute
1M ago
CORT
TEVA
Midday Fly By: Walmart reports Q4 beat, eBay to acquire Depop from Etsy
PremiumThe Fly
Midday Fly By: Walmart reports Q4 beat, eBay to acquire Depop from Etsy
1M ago
DE
VZ
Corcept Therapeutics Stock Crashes 21% after Patent Defeat to Teva
PremiumMarket News
Corcept Therapeutics Stock Crashes 21% after Patent Defeat to Teva
1M ago
CORT
TEVA
Corcept Therapeutics down 18% after appeals court ruling in Teva fight
PremiumThe FlyCorcept Therapeutics down 18% after appeals court ruling in Teva fight
1M ago
CORT
TEVA
Teva price target raised to $38 from $37 at BofA
Premium
The Fly
Teva price target raised to $38 from $37 at BofA
1M ago
SNY
TEVA
Teva Buy Rating Reinforced by Strong TL1a Phase 2 Data and $3 Billion Duvakitug Peak Sales Outlook
Premium
Ratings
Teva Buy Rating Reinforced by Strong TL1a Phase 2 Data and $3 Billion Duvakitug Peak Sales Outlook
1M ago
TEVA
Teva and Sanofi’s duvakitug Phase 2b data shows efficacy in colitis and Crohn’s
PremiumThe Fly
Teva and Sanofi’s duvakitug Phase 2b data shows efficacy in colitis and Crohn’s
1M ago
SNY
TEVA
Teva price target raised to $45 from $36 at Goldman Sachs
PremiumThe Fly
Teva price target raised to $45 from $36 at Goldman Sachs
2M ago
TEVA
Teva’s Sustainability Disclosures Face Rising Legal and Investor Risk Amid Global Compliance Demands
PremiumCompany Announcements
Teva’s Sustainability Disclosures Face Rising Legal and Investor Risk Amid Global Compliance Demands
2M ago
TEVA
Teva price target raised to $38 from $35 at Barclays
PremiumThe Fly
Teva price target raised to $38 from $35 at Barclays
2M ago
TEVA
Teva price target raised to $40 from $35 at Scotiabank
PremiumThe FlyTeva price target raised to $40 from $35 at Scotiabank
2M ago
TEVA
Teva Earnings Call: Innovation Offsets Generics and One-Offs
Premium
Company Announcements
Teva Earnings Call: Innovation Offsets Generics and One-Offs
2M ago
TEVA
Teva says targeting FY26 gross margin of 54.5%-55.5%
Premium
The Fly
Teva says targeting FY26 gross margin of 54.5%-55.5%
2M ago
TEVA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >